- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00830427
A Study To Examine The Safety And Efficacy Of PF-00610355 In Moderately Asthmatic Subjects (A7881006)
A Phase Iib Randomised Double Blind, Placebo Controlled Parallel Group Study To Investigate The Efficacy And Safety Of Pf-00610355 Over 4 Weeks In Moderate Asthmatic Subjects.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Phase
- Phase 2
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects with a physician documented history or diagnosis of persistent asthma for at least 6 months prior to Screening Visit 1.
Trough FEV1 must be 50-100% of predicted at Screening Visit 1.
Subjects who have been maintained on a stable dose of ICS over the previous month prior to screening.
Exclusion Criteria:
- Subjects who have had a severe asthma exacerbation in the 2 months prior to screening.
Subjects meeting any of the criteria of 'very poorly controlled' according to the NIH EPR 3 guidelines.
Subjects with evidence or history of cardiovascular disease including angina, myocardial, infarction, clinically significant cardiac arrhythmia (eg, atrial fibrillation, atrial flutter,supraventricular tachycardia, ventricular tachycardia), systemic hypertension (SBP > 160 mmHg or DBP >100mmHg), pulmonary hypertension or cerebrovascular disease (including transient ischaemic attacks).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
QD, dry powder inhaler
|
Experimental: PF-00610355
|
100 mcg, QD, dry powder inhaler
|
Experimental: PF - 00610355
|
600 mcg, QD, dry powder inhaler
300 mcg, QD, dry powder inhaler
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from baseline trough (24 hours post-dose) FEV1.
Time Frame: 4 weeks
|
4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from baseline in heart rate.
Time Frame: week 0, week 4
|
week 0, week 4
|
Change from baseline in trough FEV1.
Time Frame: week 4
|
week 4
|
Maximum change from baseline in FEV1 from 0 to 6 hours post-dose.
Time Frame: week 0,week 4
|
week 0,week 4
|
Change from baseline in Asthma Quality of Life Questionnaire (AQLQ-S) score.
Time Frame: week 2, week 4
|
week 2, week 4
|
Pharmacokinetics of PF-00610355.
Time Frame: week 0, week 4
|
week 0, week 4
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- A7881006
- 2008-007183-42 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Respiratory Tract Diseases
-
University of Colorado, DenverBiofireCompletedAcute Respiratory Infection | Lower Respiratory Tract Illness | Respiratory Pathogens | Upper Respiratory Tract IllnessUnited States
-
Vakzine Projekt Management GmbHFGK Clinical Research GmbHUnknownInfection, Respiratory TractGermany
-
Zambon SpACompleted
-
PfizerCompletedRespiratory Tract InfectionUnited States, Netherlands, Spain, Korea, Republic of, Denmark, Taiwan, Australia, Mexico, Canada, Japan, Finland, Argentina, Brazil, Chile, Gambia, New Zealand, Philippines, South Africa
-
GlaxoSmithKlineCompletedInfections, Respiratory TractUnited States
-
Direction Centrale du Service de Santé des ArméesRecruitingRespiratory Tract Infections | Respiratory Tract DiseaseFrance
-
PfizerCompletedRespiratory Tract InfectionUnited States, New Zealand, Chile, Argentina, South Africa
-
GlaxoSmithKlineCompletedInfections, Respiratory TractUnited States
-
AbbottEilafCompletedRespiratory Tract InfectionEgypt, Saudi Arabia
-
PfizerTerminatedRespiratory Tract InfectionUnited States, Australia
Clinical Trials on PF-00610355
-
PfizerCompletedLung Diseases | Lung Diseases, Obstructive | Pulmonary Disease, Chronic ObstructiveUnited States, Croatia, Hungary, Bulgaria, Poland, Slovakia, Germany, South Africa, Argentina, Turkey, Spain, Czechia
-
PfizerCompletedPulmonary Disease, Chronic ObstructiveGermany
-
PfizerCompletedLung Disease | Pulmonary Disease | MoxifloxacinBelgium
-
PfizerCompleted
-
University of FloridaCompletedGastrointestinal Symptoms | Stool Frequency | Gastrointestinal Transit TimeUnited States
-
PfizerCompleted
-
PfizerCompletedSchizophreniaUnited States
-
PfizerCompleted
-
PfizerCompleted